文献速递外周动脉疾病

CLTI血运重建术后强化抗栓治疗的安全性

Safety and efficacy of escalating antithrombotic therapy after lower extremity revascularization for chronic limb-threatening ischemia.
PubMed 文献 · J Vasc Surg · 2026-03-23

单中心回顾性队列纳入2005至2022年首次下肢血运重建的1286例CLTI患者,按出院抗栓方案分组。与阿司匹林单药相比,双联抗血小板、标准双通路抑制及三联治疗均与更高的消化道出血风险相关,三联治疗还与死亡率升高相关;各组心梗、卒中、原发通畅率及主要不良肢体事件无差异。

要点

  • 强化抗栓(DAPT、DPI、TT)较阿司匹林单药显著增加消化道出血风险。
  • 三联治疗较阿司匹林单药死亡风险高40%(HR 1.40,95%CI 1.01-1.95)。
  • 各组心梗、卒中、原发通畅率及MALE无显著差异。

核心结论

  • CLTI首次下肢血运重建后,抗栓治疗强度超过阿司匹林单药与更高的出血风险相关,三联治疗还与更低的生存率相关。
  • 各方案间心肌梗死、卒中、原发通畅率和主要不良肢体事件无差异,提示平衡肢体结局与出血风险仍是挑战。

研究设计与样本

  • 单中心回顾性队列研究,纳入2005至2022年首次下肢血运重建且有用药数据的CLTI患者1286例。
  • 按出院抗栓方案分为阿司匹林单药402例、P2Y12抑制剂单药85例、延长双联抗血小板359例、低剂量双通路抑制35例、标准双通路抑制257例、三联治疗148例。
  • 采用Kaplan-Meier和Cox回归分析结局。

主要发现

  • 3年消化道出血率:阿司匹林单药1.5%、P2Y12单药2.6%、双联抗血小板8.8%、低剂量双通路抑制10%、标准双通路抑制10%、三联治疗15%(P≤.001)。
  • 3年任何出血并发症率:阿司匹林单药3.2%、P2Y12单药2.6%、双联抗血小板5.8%、低剂量双通路抑制7.8%、标准双通路抑制14%、三联治疗21%(P≤.001)。
  • 3年死亡率:阿司匹林单药37%、P2Y12单药38%、双联抗血小板38%、低剂量双通路抑制44%、标准双通路抑制43%、三联治疗57%(P≤.001)。
  • 校正后较阿司匹林单药,双联抗血小板、标准双通路抑制、三联治疗的消化道出血HR分别为3.75(95%CI 1.60-8.76)、5.48(95%CI 2.11-14.2)、8.65(95%CI 3.07-24.3)。
  • 校正后标准双通路抑制和三联治疗任何出血并发症HR分别为5.07(95%CI 2.22-11.6)和9.65(95%CI 3.99-23.3);三联治疗死亡HR 1.40(95%CI 1.01-1.95)。

临床怎么用

  • CLTI术后抗栓升级前应个体化评估出血风险,尤其关注消化道出血。
  • 三联抗栓治疗与死亡率升高相关,应谨慎选择并加强监测。
  • 需与患者共同决策,权衡肢体结局与出血风险。

局限性

  • 单中心回顾性设计,可能存在选择偏倚和混杂。
  • 各抗栓组样本量差异大,低剂量双通路抑制组仅35例。
  • 基线特征组间差异显著,如房颤比例从11%至60%不等。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The VOYAGER PAD trial demonstrated the benefit of low-dose dual pathway inhibition (LD-DPI) with aspirin and low-dose rivaroxaban in select populations, yet the balance between bleeding and limb-related outcomes in real-world practice remains unclear. We aimed to compare outcomes among patients on differing antithrombotic regimens after lower extremity revascularization for chronic limb-threatening ischemia (CLTI). METHODS: All patients with available medication data undergoing first-time lower extremity revascularization for CLTI between 2005 and 2022 at a single institution were included. Patients were stratified by discharge medication regimen, including single antiplatelet therapy (SAPT; further stratified into aspirin monotherapy [SAPTasa] and P2y12 inhibitor monotherapy [SAPTp2y]), prolonged (>90 days) dual antiplatelet therapy (DAPT), LD-DPI, standard DPI (SAPT + full-dose anticoagulation), and triple therapy (TT; DAPT + anticoagulation at any dose). Primary outcomes included gastrointestinal bleeding (GIB), any bleeding complication (bleeding necessitating transfusion of ≥2 units within 48 hours, bleeding leading to surgical intervention, or intracranial hemorrhage), stroke, myocardial infarction (MI), acute limb ischemia, primary patency, major adverse limb events (MALE), and mortality. Outcomes were analyzed with Kaplan-Meier and Cox regression analyses. RESULTS: Overall, 1286 patients were included: 402 SAPTasa, 85 SAPTp2y, 359 DAPT, 35 LD-DPI, 257 DPI, and 148 TT. Baseline demographics varied, with SAPTasa and TT having the lowest and highest respective rates of coronary artery disease (49% vs 60%), hypertension (84% vs 95%), and atrial fibrillation (11% vs 60%) (all P < .05). Kaplan-Meier estimates showed significant differences between groups in 3-year rates of GIB (1.5% [SAPTasa] vs 2.6% [SAPTp2y] vs 8.8% [DAPT] vs 10% [LD-DPI] vs 10% [DPI] vs 15% [TT]), any bleeding complication (3.2% vs 2.6% vs 5.8% vs 7.8% vs 14% vs 21%), and death (37% vs 38% vs 38% vs 44% vs 43% vs 57%) (all P ≤ .001). No differences were noted in rates of MI, stroke, primary patency, or MALE. After adjustment, compared with SAPTasa, DAPT, DPI, and TT were associated with increasingly higher hazard of GIB (DAPT: hazard ratio [HR], 3.75; 95% confidence interval [CI], 1.60-8.76; DPI: HR, 5.48; 95% CI, 2.11-14.2; and TT: HR, 8.65; 95% CI, 3.07-24.3) and DPI and TT with higher hazard of any bleeding complication (HR, 5.07; 95% CI, 2.22-11.6; and HR, 9.65; 95% CI, 3.99-23.3). Compared with SAPTasa, TT had 40% higher hazard of mortality (HR, 1.40; 95% CI, 1.01-1.95). CONCLUSIONS: Escalation of antithrombotic therapy beyond SAPT after first-time lower extremity revascularization for CLTI is associated with higher bleeding risk, and TT with lower survival, possibly reflecting the vulnerability of frailer patients less able to tolerate bleeding complications. No differences were observed in MI, stroke, patency, or MALE, underscoring the challenge of balancing limb-related outcomes with bleeding risk. Careful monitoring, individualized risk stratification, and shared decision-making remain essential. Larger studies are needed to further define the relative efficacy and safety of intensified antithrombotic regimens.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Darling JD, Schermerhorn JA, Guetter CR, et al. Safety and efficacy of escalating antithrombotic therapy after lower extremity revascularization for chronic limb-threatening ischemia. J Vasc Surg. 2026. PMID: 41881317. doi:10.1016/j.jvs.2026.03.439

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。